《广州医药》
点击关注官方服务号追踪稿件状态

【重要服务提醒】《广州医药》杂志服务号已上线稿件查询功能

各位作者、审稿专家:
本刊官方微信服务号新增稿件状态查询服务,无需反复登录投稿系统,微信即可随时查看审稿进度、修回通知、录用结果,稿件更新实时推送提醒,同步接收期刊征稿、学术资讯。

操作方式

微信搜索关注广州医药杂志服务号 → 点击菜单栏「绑定账号」→ 输入投稿邮箱完成账号关联;请关闭微信消息免打扰,避免遗漏稿件通知。

《广州医药》编辑部

广州医药杂志服务号
您的位置: 首页 > 2016年3月 第47卷 第2期 > 文字全文
2023年7月 第38卷 第7期11
目录

ITP患者血清IgG型抗体糖基化特异性的研究

Study on the glycosylation specificity of the IgG antibody in ITP

来源期刊: 广州医药 | 27-28 发布时间:2021-11-30 收稿时间:2025/11/13 17:03:08 阅读量:100
作者:
关键词:
ITPIgG型抗体糖基化
Immune thrombocytopenicIgG antibodyGlycosylation
DOI:
10.3969/j.issn.1000-8535.2016.02.009
收稿时间:
2015-12-10 
修订日期:
 
接收日期:
 
引用总数:
0  
目的 分析ITP患者血清中IgG型抗体糖基化的特异性,初步探讨其特异性与临床症状的相关性。方法 选取健康献血员30例、ITP患者13例及健康怀孕妇女23例,纯化血清中的IgG型抗体,应用nano-LC-MS法分析糖基化种类及水平,对比分析ITP患者血清中IgG型抗体的糖基化特异性。结果 ① ITP 患者血清中IgG型抗体的半乳糖糖基化水平为47.08±2.69,低于健康怀孕妇女(50.93±2.21),高于健康献血员(42.88±2.00)(P<0.05);② ITP 患者岩藻糖基化水平为81.16±2.49低于健康献血员(82.60±2.56)(P>0.05),同时低于健康怀孕妇女(86.17±2.23)(P<0.05);③ITP 患者唾液酸化水平为3.93±1.20,高于健康献血员(3.69±1.19),低于健康怀孕妇女(4.28±0.88)(P>0.05)。④ITP 患者乙酰葡糖氨基化水平为10.53±1.41,低于健康献血员(11.54±1.76),高于健康怀孕妇女(10.13±1.45)(P>0.05)。结论 ITP患者血清中的IgG型抗体的岩藻糖基化、半乳糖糖基化水平的特异性可能是其产生有别于健康怀孕妇女的临床症状的的分子基础。
Objective To investigate the glycosylation specificity of the IgG antibody in ITP. Methods Choose 30 healthy donors, 23 healthy pregnants and 13 ITP patients, purified the IgG antibody from serum, analysied the level of all kinds of glycosylation. Compared with healthy donor and healthy pregnants to find the specificity of the IgG antibody in ITP patients. Results ① The galacosylation of IgG antibody in ITP patients was 47.08±7.24,lower than healthy pregnants (50.93±4.91), higher than healthy donor (42.88±4.01), and the healthy pregnants were higher than healthy donor (P<0.05). ② The fucosylation in ITP patients was 81.16±6.2, lower than healthy donors (82.60±2.56) (P>0.05), higher than healthy pregnants(86.17±2.23)(P<0.05); ③The sialylation in ITP patients was 3.93±1.20, higher than healthy donors (3.69±1.19), lower than healthy pregnants (4.28±0.88)(P>0.05); ④The GlcNAc in ITP patients was 10.53±1.41, lower than healthy donors (11.54±1.76), higher than healthy pregnants (10.13±1.45)(P>0.05). Conclusion The specificity of IgG antibody in ITP patients in galacosylation and fucosylation may be the molecule base of ITP's clinic symptom.
1、 BAKCHOUL T, WALEK K, KRAUTWURST A, et al. Glycosylation of autoantibodies: insights into the mechanisms of immune thrombocytopenica[J].Thromb Haemost, 2013, 110(6):1259-1266. BAKCHOUL T, WALEK K, KRAUTWURST A, et al. Glycosylation of autoantibodies: insights into the mechanisms of immune thrombocytopenica[J].Thromb Haemost, 2013, 110(6):1259-1266.
2、 NICOLE SAMUELS, DAVID KATES, JUN LIU, et al. Characterizing the Glycosylation State of Therapeutic Recombinant Glycoproteins[J].Methods in Molecular Biology, 2012, 951: 323-334. NICOLE SAMUELS, DAVID KATES, JUN LIU, et al. Characterizing the Glycosylation State of Therapeutic Recombinant Glycoproteins[J].Methods in Molecular Biology, 2012, 951: 323-334.
3、 ANTHONY RM, NIMMERJAHN F, ASHLINE DJ, et al. Recapitulation of IVIG anti-inflammatory activity with a recombinant IgG Fc[J].Science, 2008, 320(5874):373-376. ANTHONY RM, NIMMERJAHN F, ASHLINE DJ, et al. Recapitulation of IVIG anti-inflammatory activity with a recombinant IgG Fc[J].Science, 2008, 320(5874):373-376.
4、 HODONICZKY J, Zheng YZ, JAMES DC. Control of recombinant monoclonal antibody effector functions by Fc N-glycan remodeling in vitro[J].Biotechnol Prog, 2005, 21(6):1644-1652. HODONICZKY J, Zheng YZ, JAMES DC. Control of recombinant monoclonal antibody effector functions by Fc N-glycan remodeling in vitro[J].Biotechnol Prog, 2005, 21(6):1644-1652.
5、 BRADY LJ, VELAYUDHAN J, VISONE DB, et al. The criticality of high-resolution N-linked carbohydrate assays and detailed characterization of antibody effector function in the context of biosimilar development[J].MAbs. 2015,7(3):562-570. BRADY LJ, VELAYUDHAN J, VISONE DB, et al. The criticality of high-resolution N-linked carbohydrate assays and detailed characterization of antibody effector function in the context of biosimilar development[J].MAbs. 2015,7(3):562-570.
6、 KAPUR R, DELLA VALLE L, Sonneveld M,et al. Low anti-RhD IgG-Fc-fucosylation in pregnancy: a new variable predicting severity in haemolytic disease of the fetus and newborn[J].J Rheumatol. Br J Haematol,2014,166(6):936-945. KAPUR R, DELLA VALLE L, Sonneveld M,et al. Low anti-RhD IgG-Fc-fucosylation in pregnancy: a new variable predicting severity in haemolytic disease of the fetus and newborn[J].J Rheumatol. Br J Haematol,2014,166(6):936-945.
7、 CLERC F, REIDING KR, JANSEN BC, et al. Human plasma protein N-glycosylation[J].Glycoconj J, 2015, 10. CLERC F, REIDING KR, JANSEN BC, et al. Human plasma protein N-glycosylation[J].Glycoconj J, 2015, 10.
8、 WANG J, ZHOU C, ZHANG W, et al. An integrative strategy for quantitative analysis of the N-glycoproteome in complex biological samples[J].Proteome Sci,2014, 15,12(1):4. WANG J, ZHOU C, ZHANG W, et al. An integrative strategy for quantitative analysis of the N-glycoproteome in complex biological samples[J].Proteome Sci,2014, 15,12(1):4.
9、 MCMILLAN R. The pathogenesis of chronic immune thrombocytopenic purpura[J].Semin Hematol,2007,44(4 Suppl 5):S3-S11. MCMILLAN R. The pathogenesis of chronic immune thrombocytopenic purpura[J].Semin Hematol,2007,44(4 Suppl 5):S3-S11.
上一篇
下一篇
出版者信息








《广州医药》公众号
目录